Worth the read: new Circulation series of 2-page statistical reviews for clinicians.

Inaugural article on summarizing results of time-to-event endpoints is now published.

Couldn't think of better people than Andrea Bellavia and Sabina Murphy to lead this effort.

TIMI Study Group

Thank you for the kind words Sam Tsimikas, MD. It’s been our privilege to learn from you and your team over the past couple of years.

I have worked with both of them closely on olezarsen, whoever hires them in their next job will be a BIG winner!

Elderly pts with ASCVD derive similar to greater CV benefit compared to younger pts with early initiation of #evolocumab up to 8.6 yrs with no significant safety concerns. These findings may be helpful in guiding future US recommendations. Samer Alsaid Robert Giugliano #ACC24

Among patients with #T2DM enrolled in the DECLARE-TIMI 58 trial, soluble ST2 is independently associated with higher risk for multiple adverse CV outcomes, with consistent benefit of #dapagliflozin for CVD/HHF across baseline sST2 concentrations Paul M Haller Stephen Wiviott #ACC24

👉🏼 SGLT2i ⬇️ risk of MACE across broad range of pt populations & key subgroups 👉🏼 Benefit primarily driven by ⬇️ CV death, particularly ⬇️ HF death & SCD #SimPub in Circulation from Sid M. Patel Yumi Kang, MD, PhD Stephen Wiviott SGLT2 Trialists Consortium #ACC24
ahajournals.org/doi/10.1161/CI…

In a patient-level meta-analysis of the 4 pivotal DOAC trials, DOACs consistently reduced thromboembolic and bleeding events, and did not affect MI versus warfarin, irrespective of baseline ASCVD status André Zimerman Robert Giugliano #ACC24

Primary results from Bridge-TIMI 73a Late Breaking Clinical Trial presented by Brian Bergmark at #ACC24 show that #olezarsen reduces #triglyceride levels by ~50% without major safety concerns. Now published in NEJM. Nicholas Marston

You should consider switching frail, elderly, VKA-experienced AF pts to a DOAC – results from a much larger, longer, randomized analysis of COMBINE-AF show more favorable outcomes with DOACS and do not support FRAIL-AF trial findings. Robert Giugliano @andrezimerman #ACC24

In FOURIER, intensive LDL-C lowering with #evolocumab led to greater CV event reduction in patients with autoimmune or inflammatory diseases. These patients may derive particular benefit from earlier, more intensive lipid-lowering treatments. Robert Giugliano André Zimerman #ACC24

In 24 hrs in Moderated Poster Theatre 08, André Zimerman presents his poster, 'Cardiovascular Benefit of Evolocumab in 27,564 Patients With And Without Autoimmune Or Inflammatory Disease: An Analysis Of The #FOURIER Trial Robert Giugliano #ACC24

In pts w/elevated triglycerides, vupanorsen, an ANGPTL3 inhibitor, lowered remnant cholesterol by up to 59% & VLDL cholesterol by up to 67% over placebo. ANGPTL3i may be a promising approach for lowering cholesterol on triglyceride-rich lipoproteins doi.org/10.1093/eurjpc…

The🧠efficacy &🩸safety of 💊 #NOAC vs. #warfarin in underweight or obese pts w/ #AF remains uncertain.

👇🏽Now in Circulation, we leveraged COMBINE to perform an IPD M-A of pivotal NOAC vs. warfarin RCTs (>58k 👥) to examine 💊 effect across BMI & BW.

ahajournals.org/doi/10.1161/CI…